Jana Prausová

Proton Therapy Centre — Czech Republic

Medicine · Health Sciences

25h-index7.1kcitations93works76.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(40), Cancer Treatment and Pharmacology(22), Gastric Cancer Management and Outcomes(21), Hepatocellular Carcinoma Treatment and Prognosis(12), Lung Cancer Treatments and Mutations(11)

Publications92 total

CLINICAL EXPERIENCE WITH PROTON RT IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL HEMATOLOGIC MALIGNANCIES TREATED WITH CAR T-CELL THERAPY
International Journal of Particle Therapy·2025Open Access
Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety
Radiotherapy and Oncology·2025· 1 citedOpen Access
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology·2024· 175 citedOpen Access
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Journal of Clinical Oncology·2024· 129 citedOpen Access
https://www.prolekare.cz/en/journals/transfusion-and-haematology-today/2023-1-15/recommendations-for-thrombotic-risk-stratification-and-targeted-thromboprophylaxis-in-women-during-assisted-reproduction-133823
Transfuze a hematologie dnes·2023· 2 cited
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
Breast Cancer Research and Treatment·2021· 97 citedOpen Access
Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes
International Journal of Radiation Oncology*Biology*Physics·2021· 18 cited
Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).
Journal of Clinical Oncology·2021· 4 cited
The possibilities of molecular testing of somatic aberrations in tumor tissue using NGS in routine practice - current situation in the Czech Republic.
PubMed·2021
Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database
Neoplasma·2020· 4 citedOpen Access
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
SHILAP Revista de lepidopterología·2020· 2 citedOpen Access
<p>Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients</p>
Cancer Management and Research·2020· 15 citedOpen Access
Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers
Annals of Oncology·2019· 7 citedOpen Access
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology·2019· 276 citedOpen Access
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting
Oncology Research and Treatment·2019· 5 cited
Supplementary Material for: Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting
Figshare·2019Open Access
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
Annals of Oncology·2018· 63 citedOpen Access
Regorafenib for metastatic colorectal carcinoma: A registry-based analysis
Annals of Oncology·2018Open Access
Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS)
Annals of Oncology·2018· 3 citedOpen Access
Are <i>BRAF</i> mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.
Journal of Clinical Oncology·2018· 6 cited
page 1 of 5Next →

Frequent Co-authors

Eric Van Cutsem(23), Josep Tabernero(17), Bohuslav Melichar(16), G. Bodoky(13), Radka Obermannová(11), Radek Lakomý(10), Rocio García‐Carbonero(10), Tudor–Eliade Ciuleanu(10), David C. Portnoy(10), Federico Nasroulah(10), Paul Ruff(9), Vladimir Moiseyenko(9), Takayuki Yoshino(9), Allen Lee Cohn(9), Kentaro Yamazaki(9), David Ferry(8), Tomáš Büchler(8), Sara Lonardi(7), Zbyněk Bortlíček(6), Zdeněk Linke(6)